Compare SIMO & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIMO | ALKS |
|---|---|---|
| Founded | 1995 | 1987 |
| Country | Hong Kong | Ireland |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 7.5B |
| IPO Year | 2005 | 2012 |
| Metric | SIMO | ALKS |
|---|---|---|
| Price | $302.95 | $53.62 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 14 |
| Target Price | ★ $118.13 | $43.43 |
| AVG Volume (30 Days) | 974.2K | ★ 2.4M |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.92% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,475,899,000.00 |
| Revenue This Year | $42.27 | $24.26 |
| Revenue Next Year | $12.78 | $4.47 |
| P/E Ratio | $36.09 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $70.12 | $25.17 |
| 52 Week High | $355.00 | $53.69 |
| Indicator | SIMO | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 55.52 | 86.15 |
| Support Level | $234.60 | $27.65 |
| Resistance Level | $314.34 | N/A |
| Average True Range (ATR) | 22.76 | 1.97 |
| MACD | 0.25 | 0.75 |
| Stochastic Oscillator | 53.18 | 88.10 |
Silicon Motion Technology Corp is engaged in developing NAND flash controllers for SSDs and other solid-state storage devices. Its only operating segment is to develop NAND flash controllers and SSD solutions. The company derives revenue from product categories such as Mobile Storage, Mobile Communications, and others. Silicon's geographical segments are Taiwan, the United States, Korea, China, Singapore, Malaysia, and others. The company's products are used in Personal Computing, Smartphone/Tablet/CE, Flash Card/USB Flash Drive, Industrial and Embedded, Automotive, and Enterprise and Data centers.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.